WS Audiology loses USD 600m across two years – still withholds net profit guidance

Hearing-aid manufacturer WS Audiology has operated with resounding losses in its two years after the Widex-Sivantos merger, but the executive team declines to comment on when the group expects to present black bottom-line figures. Interest-bearing debt of EUR 3.6bn makes it tough to predict, the company says.

Søren Westh Lonning, CFO of WS Audiology | Photo: WS Audiology / PR

It's been poor business as of late, to put it mildly, being hearing-aid manufacturer WS Audiology, which following the major merger of Danish Widex and EQT-owned Sivantos from Germany – which became a reality in 2019 – could otherwise claim the title as the world's third-largest hearing-aid supplier.

In 2018/2019, the first full fiscal year after the merger, the Copenhagen-headquartered company booked an operating deficit of DKK 2.14bn (USD 350m), and on Thursday the group presented its annual report for fiscal 2019-'20, showing another big loss of DKK 1.8bn and 11 percent in negative organic growth.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs